114 related articles for article (PubMed ID: 3965629)
1. Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors.
Davila E; Klein L; Vogel CL; Johnson R; Ostroy F; Browning S; Gorowski E; Furner RL; Presant CA
J Clin Oncol; 1985 Jan; 3(1):121-7. PubMed ID: 3965629
[TBL] [Abstract][Full Text] [Related]
2. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
3. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma.
Glover D; Trump D; Kvols L; Elson P; Vogl S
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1405-8. PubMed ID: 3759565
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.
Bailey H; Mulcahy RT; Tutsch KD; Rozental JM; Alberti D; Arzoomanian RZ; Tombes MB; Trump DL; Wilding G
Cancer Res; 1991 Feb; 51(4):1099-104. PubMed ID: 1825475
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
[TBL] [Abstract][Full Text] [Related]
7. High-dose melphalan, misonidazole, and autologous bone marrow transplantation for the treatment of metastatic colorectal carcinoma. A phase I study.
Spitzer TR; Lazarus HM; Creger RJ; Berger NA
Am J Clin Oncol; 1989 Apr; 12(2):145-51. PubMed ID: 2650527
[TBL] [Abstract][Full Text] [Related]
8. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.
Sparano JA; Robert N; Silverman P; Lazarus H; Malik U; Venkatraj U; Sarta C
J Clin Oncol; 1996 Sep; 14(9):2576-83. PubMed ID: 8823338
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
[TBL] [Abstract][Full Text] [Related]
12. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of cyclophosphamide (NSC 26271) by 72-hour continuous intravenous infusion.
Bedikian AY; Bodey GP
Am J Clin Oncol; 1983 Jun; 6(3):365-8. PubMed ID: 6846253
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.
Tchekmedyian NS; Egorin MJ; Cohen BE; Kaplan RS; Poplin E; Aisner J
Cancer Chemother Pharmacol; 1986; 18(1):33-8. PubMed ID: 3757157
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
Semin Oncol; 1998 Feb; 25(1 Suppl 2):23-8. PubMed ID: 9535208
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
17. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
Tolcher AW; Cowan KH; Noone MH; Denicoff AM; Kohler DR; Goldspiel BR; Barnes CS; McCabe M; Gossard MR; Zujewski J; O'Shaughnessy JA
J Clin Oncol; 1996 Jan; 14(1):95-102. PubMed ID: 8558227
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel and cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):21-3. PubMed ID: 9213323
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
